The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Novartis Eyes Market Penetration with pNET Indication for Afinitor, Prolonged QOL for Patients
January 26, 2012
- Abbott Sets Up New Unit With MRs Specializing in CNS, Anesthetics for Luvox Transfer
January 26, 2012
- Nippon Kayaku’s Nambu Stresses Need for Collaboration between Medium-Sized Companies in Biosimilars
January 26, 2012
- Taiyo, Teva-Kowa to Establish Teva Pharma Japan in April, with 7 Branches, 29 Sales Offices Nationwide
January 26, 2012
- 301 MSs from Medipal HD Pass 18th MR Examination
January 26, 2012
- Achievement of SVR12 with DAA-only Combination Therapy Possible in Hepatitis C: BMS
January 26, 2012
- Toho HD Upwardly Revises FY2012 Earnings Forecast Expecting Boosted Sales, Profits
January 25, 2012
- Nichi-Iko, Sanofi to Jointly Develop Remicade Biosimilar
January 25, 2012
- Pfizer Japan Launches Zithromac for Intravenous Use
January 25, 2012
- CMIC HD to Merge 2 CRO Subsidiaries
January 25, 2012
- Mochida President Hopes to Ease Impact of Next NHI Price Revision with New Drugs
January 24, 2012
- Seikagaku Initiates PII Trial for SI-614 for Dry Eye in US
January 24, 2012
- Sosei Announces Collaboration with CEOLIA Pharma
January 24, 2012
- Wakamoto Pharmaceutical Withholds Joint Venture Plan with Major Taiwanese Generics Company
January 23, 2012
- Astellas to Transfer 3 Drugs to Choseido including Tathion
January 23, 2012
- Indications for Alveolar Pyorrhea Removed from Lysozyme HCl
January 23, 2012
- Growell President Takada Says Ready for Legal Action on Stoppage of “Dispensing Point” System
January 23, 2012
- NPhA’s Iwasaki Says Strength in Securing Profit Weak
January 23, 2012
- GSK Obtains Approval for Paxil CR Tablets, to Comarket with DSP
January 20, 2012
- No. of Patients Not Recommended to Take Generics Down to 40%: Sawai Survey
January 20, 2012
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…